Company profile: Ondine Biomedical
1.1 - Company Overview
Company description
- Provider of non-antibiotic, anti-infective therapies for bacterial, viral, and fungal infections, including Steriwave nasal decolonization that eradicates pathogens in minutes (MRSA, SARS-CoV-2), Photodisinfection using a photosensitive agent and non-thermal laser light to destroy pathogens without resistance, and an Expanded Access Program for investigational medicines prior to regulatory approval.
Products and services
- Photodisinfection: Non-thermal technology that applies a photosensitive agent with laser light to immediately destroy bacterial, viral, and fungal pathogens without resistance formation, enabling broad-spectrum anti-infective therapy
- Steriwave: Non-antibiotic nasal decolonization therapy that eradicates pathogens in the nose within minutes, targeting bacteria and viruses including MRSA and SARS-CoV-2
- Expanded Access Program (EAP): Investigational program that offers patients facing serious conditions access to medicines prior to regulatory approval under specific circumstances.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ondine Biomedical
Turn Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceutical solutions to reduce the human and economic costs of infection and skin disease, including PermaFusion petrolatum-based liquid-in-oil suspension technology for high-bioavailability delivery; Hexagen FDA-cleared antimicrobial wound dressing; a pre-operative nasal decolonization program targeting MRSA; and onychomycosis treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Turn Therapeutics company profile →
Cytophage
HQ: Canada
Website
- Description: Provider of bacteriophage development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cytophage company profile →
Entasis Therapeutics
HQ: United States
Website
- Description: Provider of anti-infective therapies for serious drug-resistant bacterial infections. Products include GIAPREZA (angiotensin II to increase blood pressure in septic or distributive shock), XERAVA (eravacycline for complicated intra-abdominal infections), XACDURO (sulbactam/durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex), and zoliflodacin (Phase 3 for uncomplicated gonorrhea).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entasis Therapeutics company profile →
OLM Diagnostics
HQ: United Kingdom
Website
- Description: Provider of fungal and bacterial diagnostic solutions for healthcare providers, including: AspLFD, a lateral flow device detecting Aspergillus antigens in 15–40 minutes; AspID and PneumID real-time PCR kits for Aspergillus species (90 minutes) and Pneumocystis jirovecii (45 minutes); CandID for early Candida bloodstream detection; and AurisID for identifying Candida auris.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OLM Diagnostics company profile →
BioVersys
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies and novel antibacterial products to combat multidrug-resistant bacterial infections, developing new mode-of-action compounds that switch off drug resistance and restore efficacy of approved antibiotics across Gram-negative, Gram-positive, and Tuberculosis pathogens, with a pipeline advancing through human clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVersys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ondine Biomedical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ondine Biomedical
2.2 - Growth funds investing in similar companies to Ondine Biomedical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ondine Biomedical
4.2 - Public trading comparable groups for Ondine Biomedical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →